Drug Trial Radar · NCT04743505
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
27
Actual
Start
Jan 18, 2022
Primary completion
Jan 31, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Apollomics Inc.
- First posted
- Feb 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have received at least 8 and not more than 12 weeks of treatment with osimertinib without demonstrating disease progression, will receive APL-101 in combination with osimertinib until progression. Dosing of APL-101 will be escalated until the maximum tolerated dose is determined, at which point 10 additional patients will be enrolled at that dose in the expansion cohort.
Conditions
- Metastatic Non Small Cell Lung Cancer
Interventions
APL-101Drug
-Provided by Apollomics
OsimertinibDrug
-Given standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Toxicity as measured by number of study treatment related adverse events (Phase I only)Time frame: Through 30 days after last dose of treatment (estimated to be 21 months)
- Toxicity as measured by number of study discontinuations due to treatment-related adverse events (Phase I only)Time frame: Through 30 days after last dose of treatment (estimated to be 21 months)
- Progression-free survival (PFS) (Phase II or received MTD only)Time frame: At 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.